EE632 Winning the COVID-19 Vaccine Race: How to Launch a Premium Priced COVID-19 Vaccine in a Competitive and Saturated Cost-Effectiveness Market

Detalles Bibliográficos
Autores principales: Folorunso, R, Vyas, H, Perez, L, O'Brien, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747377/
http://dx.doi.org/10.1016/j.jval.2022.09.871
_version_ 1784849582835892224
author Folorunso, R
Vyas, H
Perez, L
O'Brien, M
author_facet Folorunso, R
Vyas, H
Perez, L
O'Brien, M
author_sort Folorunso, R
collection PubMed
description
format Online
Article
Text
id pubmed-9747377
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-97473772022-12-14 EE632 Winning the COVID-19 Vaccine Race: How to Launch a Premium Priced COVID-19 Vaccine in a Competitive and Saturated Cost-Effectiveness Market Folorunso, R Vyas, H Perez, L O'Brien, M Value Health Article Published by Elsevier Inc. 2022-12 2022-12-14 /pmc/articles/PMC9747377/ http://dx.doi.org/10.1016/j.jval.2022.09.871 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Folorunso, R
Vyas, H
Perez, L
O'Brien, M
EE632 Winning the COVID-19 Vaccine Race: How to Launch a Premium Priced COVID-19 Vaccine in a Competitive and Saturated Cost-Effectiveness Market
title EE632 Winning the COVID-19 Vaccine Race: How to Launch a Premium Priced COVID-19 Vaccine in a Competitive and Saturated Cost-Effectiveness Market
title_full EE632 Winning the COVID-19 Vaccine Race: How to Launch a Premium Priced COVID-19 Vaccine in a Competitive and Saturated Cost-Effectiveness Market
title_fullStr EE632 Winning the COVID-19 Vaccine Race: How to Launch a Premium Priced COVID-19 Vaccine in a Competitive and Saturated Cost-Effectiveness Market
title_full_unstemmed EE632 Winning the COVID-19 Vaccine Race: How to Launch a Premium Priced COVID-19 Vaccine in a Competitive and Saturated Cost-Effectiveness Market
title_short EE632 Winning the COVID-19 Vaccine Race: How to Launch a Premium Priced COVID-19 Vaccine in a Competitive and Saturated Cost-Effectiveness Market
title_sort ee632 winning the covid-19 vaccine race: how to launch a premium priced covid-19 vaccine in a competitive and saturated cost-effectiveness market
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747377/
http://dx.doi.org/10.1016/j.jval.2022.09.871
work_keys_str_mv AT folorunsor ee632winningthecovid19vaccineracehowtolaunchapremiumpricedcovid19vaccineinacompetitiveandsaturatedcosteffectivenessmarket
AT vyash ee632winningthecovid19vaccineracehowtolaunchapremiumpricedcovid19vaccineinacompetitiveandsaturatedcosteffectivenessmarket
AT perezl ee632winningthecovid19vaccineracehowtolaunchapremiumpricedcovid19vaccineinacompetitiveandsaturatedcosteffectivenessmarket
AT obrienm ee632winningthecovid19vaccineracehowtolaunchapremiumpricedcovid19vaccineinacompetitiveandsaturatedcosteffectivenessmarket

Ejemplares similares